Parents will still be able to seek out shots from rival drugmaker Moderna, the other maker of mRNA vaccines, which has full ...

Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus ...

The Food and Drug Administration rescinded the emergency use authorization that made COVID-19 shots available for healthy ...

U.S. Health Secretary Robert F. Kennedy Jr. stated on Wednesday that the Food and Drug Administration (FDA) has now granted ...

The Food and Drug Administration gave the greenlight to updated COVID-19 shots Wednesday, maintaining unrestricted access for all Americans 65 and older while significantly limiting eligibility for ...

The American Academy of Pediatrics called the decision to limit children's access to COVID-19 vaccines “deeply troubling.” ...

Retail investor chatter around vaccine makers Novavax, Moderna, and Pfizer rose on Wednesday, ahead of a closely watched CDC vaccine advisory meeting. At Wednesday’s close, Novavax closed down 0 ...

Investing.com -- Moderna Inc (NASDAQ:MRNA) stock fell 5.5% and Pfizer Inc (NYSE:PFE) shares dropped 2.6% following reports ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna’s patents at London’s Court of Appeal.

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday.

The pioneering work for the Moderna COVID-19 vaccine, which was granted emergency use authorization by the FDA, and the Pfizer vaccine began at the University of Pennsylvania more than a decade ago.